Thyroid cancer medullary · 2 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~8.3 mo | ~32.4 mo | ~10 | ~R 334 331 PFS proxy · indirect | 36 |
Axitinib monotherapy Variant #01 | — | R 21 402 | 28d | ~9.2 mo | ~20.9 mo | ~11 | ~R 235 420 PFS proxy · indirect | 4 |
2 of 2 regimens shown